CRISPR Therapeutics AG Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 4, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	4,781	3,360	4,972	3,183	5,799	10,818
Market Cap Growth	39.00%	-32.44%	56.24%	-45.12%	-46.39%	198.74%
Enterprise Value	2,934	1,651	3,474	1,452	3,527	9,501
Last Close Price	52.00	39.36	62.60	40.65	75.78	153.11
PE Ratio	-	-	-	-	15.36	-
PS Ratio	118.63	90.03	13.40	2656.64	6.34	15045.33
PB Ratio	2.55	1.74	2.64	1.70	2.42	6.50
P/TBV Ratio	2.44	1.74	2.64	1.70	2.42	6.50
P/FCF Ratio	-	-	-	-	12.68	-
P/OCF Ratio	-	-	-	-	10.76	-
EV/Sales Ratio	76.53	44.26	9.36	1211.76	3.86	13213.93
EV/EBITDA Ratio	-	-	-	-	9.01	-
EV/EBIT Ratio	-	-	-	-	9.44	-
EV/FCF Ratio	-	-	-	-	7.71	-
Debt / Equity Ratio	0.11	0.12	0.13	0.13	0.09	0.04
Debt / EBITDA Ratio	-	-	-	-	0.53	-
Debt / FCF Ratio	-	-	-	-	0.49	-
Asset Turnover	0.02	0.02	0.17	0	0.40	0
Quick Ratio	16.10	22.00	17.47	15.08	19.92	18.05
Current Ratio	16.22	22.07	17.54	15.30	20.17	18.21
Return on Equity (ROE)	-25.33%	-19.20%	-8.17%	-30.42%	18.59%	-26.80%
Return on Assets (ROA)	-13.28%	-13.04%	-6.22%	-16.85%	10.20%	-15.30%
Return on Invested Capital (ROIC)	-229.52%	-137.29%	-60.81%	-244.99%	264.84%	-848.71%
Return on Capital Employed (ROCE)	-22.50%	-21.70%	-10.50%	-31.70%	14.20%	-20.40%
Earnings Yield	-10.46%	-10.90%	-3.09%	-20.43%	6.51%	-3.23%
FCF Yield	-6.50%	-4.31%	-5.43%	-16.74%	7.89%	-2.37%
Buyback Yield / Dilution	-5.48%	-6.49%	-1.90%	3.29%	-21.90%	-15.84%

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q